Clinical Trial Update: A Study of JNJ-88998377 for Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 study update for JNJ-88998377 in relapsed/refractory B-cell non-Hodgkin lymphoma; the trial is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• JNJ-88998377

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Lymphoma, Non-Hodgkin, Refractory B-Cell NHL | Phase 1 | Status: ACTIVE_NOT_RECRUITING